Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice.
We have previously shown that bovine lactoferrin (BLF) given intravenously (i.v.) protected mice against a lethal dose of Escherichia coli and strongly stimulated both the clearing and killing activities in liver, lungs, spleen and kidney. Since some studies indicated a reduction of the manifestation of experimental pancreatitis with lactoferrin (LF), we decided to examine the protective activity of BLF against lethal E. coli infection in animals with alloxan (Alx)-induced diabetes. It appeared that 48 h diabetes substantially lowered the killing activity in all four organs as well as the clearing rate of E. coli from the circulation. BLF given i.v. reduced this undesirable effect of diabetes. However, in 10- and 20-day diabetic animals, the diabetes alone stimulated the killing activity in the organs investigated, and upregulated the clearing rate of E. coli from the circulation. Lactoferrin significantly increased both the killing and the clearing activity in these long-term diabetic animals. In some cases the stimulating effect of BLF was very high, suggesting a concerted action of BLF and diabetes in that category of mice. Despite these beneficial effects of BLF and diabetes on the killing process in the investigated organs, the survival time of animals from all the diabetic groups (48 h, 10 and 20 days) was not prolonged by BLF. The protective properties of BLF did not depend on the blood glucose levels in the diabetic animals. BLF partly delayed the development of experimental Alx-induced diabetes, measured by the glucose level, but only if administered shortly after Alx injection. In conclusion, we demonstrated that the state of diabetes alone could increase killing of bacteria in the investigated organs and LF enhanced this process. However, LF had no protective effect against the mortality of diabetic mice infected with a lethal dose of E. coli.
Zagulski
T
T
Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Wó1ka Kosowska. zagulski@yahoo.com
Jarzabek
Z
Z
Zagulska
A
A
Jaszczak
M
M
Kochanowska
I E
IE
Zimecki
M
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002417:Cattle; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000502:physiology*; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D007781:Lactoferrin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D051379:Mice; D015996:Survival Rate
D001786:Blood Glucose; D007781:Lactoferrin